SEC Form 4 · accession 0001171843-18-001104

Sucampo Pharmaceuticals, Inc. · SCMP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Science Officer

Period of report

Feb 13, 2018

Accepted (ET)

Feb 13, 2018 · 4:51 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001365216

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, Class A^F1	Feb 13, 2018	D	44,856	$18.00	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F2	$8.33	Feb 13, 2018	D	250,000	D	—	Oct 27, 2024	Common Stock	250,000	D
Stock Option (right to buy)^F2	$14.82	Feb 13, 2018	D	38,500	D	—	Mar 4, 2025	Common Stock	38,500	D
Stock Option (right to buy)^F2	$13.80	Feb 13, 2018	D	87,203	D	—	Mar 2, 2026	Common Stock	87,203	D
Stock Option (right to buy)^F2	$11.85	Feb 13, 2018	D	133,000	D	—	Mar 2, 2027	Common Stock	133,000	D

F1This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").
F2This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.